Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ioforminol 160 mgI/mL · 1 trial · 1 indication
Quantitative measurement of the radiographic density (as measured by Hounsfield Units (HU) ) at the abdominal aorta at the level of the celiac artery. The greater the contrast attenuation, the higher the HU.
Quantitative measurement of the radiographic density (as measured by Hounsfield Units (HU) ) at the abdominal aorta at the level of the celiac artery. The greater the contrast attenuation, the higher the HU.
| Arm | Type | Description |
|---|---|---|
| Arm 1 - Ioforminol 160mgI/mL | EXPERIMENTAL | Single administration of Ioforminol 160mgI/mL given to the subject. |
| Arm 2 - Ioforminol 200mgI/mL | EXPERIMENTAL | Given as a single administration to the subject |
| Arm 3 - Iopamidol 300mgI/mL | ACTIVE_COMPARATOR | Given as a single administration to the subject |
| Name | Type | Description |
|---|---|---|
| Ioforminol 160 mgI/mL | DRUG | Given as s single administration to the subject |
| Ioforminol 200 mgI/mL | DRUG | Given as a single administration to the subject |
| Iopamidol 300 mgI/mL | DRUG | Given as a single administration to the subject |
Inclusion Criteria: * Healthy males or females between 18 and 50 years of age. * The subject has a maximum abdominal circumference of 120 cm or less. Exclusion Criteria: * The subject has known Grade 3 or 4 allergic reaction/hypersensitivity to either iodine or any iodinated-based contrast agent ...
Ioforminol 160 mgI/mL is an investigational small molecule being studied for use in abdominal contrast-enhanced computed tomography (CECT) in healthy volunteers. It is a low-concentration iodine-based contrast agent intended for imaging applications. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Ioforminol 160 mgI/mL is being developed by GE HealthCare Technologies Inc., a company traded on the New York Stock Exchange under the ticker GEHC. The company is conducting clinical research to evaluate this contrast agent for use in abdominal imaging procedures.
Ioforminol 160 mgI/mL is in Phase 1 clinical development. It is an investigational drug that has not yet received regulatory approval. The Phase 1 trial has been completed, and the drug remains under investigation for its intended use in abdominal contrast-enhanced computed tomography.
Ioforminol 160 mgI/mL has one completed Phase 1 clinical trial registered as NCT01672996. This open-label, randomized study evaluated low concentration Ioforminol injections for use in abdominal CECT in healthy volunteers. The trial enrolled 66 participants in the United States and was actively controlled.
Ioforminol 160 mgI/mL is a distinct investigational contrast agent developed by GE HealthCare. It is formulated at a low iodine concentration of 160 mgI/mL for use in imaging procedures. No alternative names for this specific drug have been disclosed in clinical trial registrations.